Abstract 4565
Background
With the wide introduction of anti-PD-1 agents in the treatment of NSCLC, the unusual patterns of response are now observed more frequently in the clinical setting. One of the major concerns for clinicians is hyperprogression, perceived as a reality by many but for which there is still discussion and has no standard definition. The aim of our work was to analyse the patterns of response to nivolumab in a homogeneously treated population of patients with NSCLC and identify cases with hyperprogression.
Methods
Between December 2015 and August 2017, 42 patients with NSCLC were treated with Nivolumab at 3mg/kg every 2 weeks. A retrospective evaluation of the CT scans (previous to baseline, baseline before nivolumab, subsequent scans after nivolumab) was performed by a thoracic radiologist. Tumour growth rate was defined as the percentage of variation by RECIST1.1 over time. It was calculated for the pre and post-nivolumab period (RECIST%/time (days)). We defined hyperprogressors as those patients whose tumour growth was 2 times greater on nivolumab than in the pre-nivolumab period.
Results
RECIST 1.1 evaluation was feasible in 40 patients. Best response was a partial response in 17.5% patients, including 4 cases (10%) of pseudoprogression and 2 cases with delayed response (after 1st scan). Thirty percent and 52.5% of patients showed stable disease and progressive disease, respectively. Among the 20 patients who developed progression by RECIST 1.1 on nivolumab, 16 experienced a more rapid progression in the post-nivolumab period (median % of change/t 0.6 Vs 0.3 in the pre-nivolumab period; p = 0.02)). Sixty percent (12/20) of progressing patients were hyperprogressors according to our definition (30% of the total population). No differences between hyperprogressors vs rest of progressors according to age, performance status, treatment line, gender or histology was observed.
Conclusions
Rare patterns of response (pseudoprogression, hyperprogression) must be considered in the evaluation of patients treated with immunotherapy. Unexpectedly rapid progressions are observed on immunotherapy. Standardized definitions and mechanisms for these events warrant further investigation.
Clinical trial identification
Legal entity responsible for the study
Hospital del Mar.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract